At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 14 enrolled
Drug / intervention
VPD-737 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Trial of Neurokinin-1 Receptor Antagonist for the Treatment of Itch in Epidermolysis Bullosa Patients
In Brief
A Phase 2 clinical trial evaluating VPD-737 and Placebo for Epidermolysis Bullosa and Pruritus. Completed, enrolled 14 participants across 1 site.
Detailed Summary
Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and safe in treating moderate to severe pruritus in patients with Epidermolysis Bullosa (EB).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpidermolysis Bullosa, Pruritus
CountriesUnited States
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartAug 2016
Primary CompletionJun 2018
Study CompletionJul 2018
TodayJul 2026
First PostedJan 13, 2016
Enrollment StartAug 31, 2016
Primary CompletionJun 28, 2018
Study CompletionJul 27, 2018
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 10.5 years ago
Interventions
VPD-737drug
VPD-737 inhibits the receptor neurokinin-1.
Placeboother
Matching tablets to VPD-737 tablets without active drug